New insider activity at Arcutis Biotherapeutics ( (ARQT) ) has taken place on June 17, 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Director Patrick Heron has made a significant investment in Arcutis Biotherapeutics by purchasing 2,646 shares of the company’s stock, valued at $34,609.
Recent Updates on ARQT stock
Arcutis Biotherapeutics recently held its 2025 Annual Meeting of Stockholders, where all proposed matters were approved, including the election of directors and the ratification of its auditor. The company also announced the enrollment of the first child in a Phase 2 study for its ZORYVE cream in infants with atopic dermatitis, and the FDA approved a supplemental New Drug Application for Zoryve topical foam for treating plaque psoriasis. These developments, alongside strong revenue growth and a promising pipeline, have contributed to a positive outlook from analysts, despite challenges such as persistent unprofitability and valuation issues. The FDA approval and the potential market for Zoryve foam are key factors driving the buy rating from analysts.
Spark’s Take on ARQT Stock
According to Spark, TipRanks’ AI Analyst, ARQT is a Neutral.
Arcutis Biotherapeutics scores moderately due to robust revenue growth and promising pipeline developments. However, persistent unprofitability, negative cash flows, and valuation challenges weigh on the score. The mixed technical indicators and positive corporate event contribute modestly to the overall assessment.
To see Spark’s full report on ARQT stock, click here.
More about Arcutis Biotherapeutics
YTD Price Performance: -7.97%
Average Trading Volume: 2,225,178
Technical Sentiment Signal: Buy
Current Market Cap: $1.6B